Marlinspike has brought together a powerful platform underpinned by unique synthetic lethality screens in relevant biological contexts to identify key cancer vulnerabilities. To rapidly target these vulnerabilities, Marlinspike uses an integrated modern medicinal chemistry platform spanning: biochemistry, structural biology, molecular dynamics, and medicinal chemistry to develop both covalent and non-covalent modulators. Marlinspike Therapeutics has established a state-of-the-art laboratory in Cambridge, MA, and is funded through Series A by Apple Tree Partners (ATP), a leader in life sciences venture capital, with $2.65 billion in committed capital.

We are looking for candidates who are keen experimentalists, independent thinkers, and enthusiastic team players that have a passion for drug discovery!